Status: Not yet recruiting
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
Participants needed: 44
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUpdated: May 13, 2026Locations: 5
Eligibility criteria
Subjects voluntarily participate in clinical studies. [+16]
Active infections such as hepatitis and tuberculosis. [+3]